| Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis. | |
| | |
MedLine Citation:
|
PMID: 10116116 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical trials have shown that the murine monoclonal antibody E5 and the human hybrid monoclonal antibody HA-1A increase survival of patients with gram-negative sepsis. However, significant reduction in mortality associated with E5's use was limited to patients who had not progressed to refractory shock. Patients treated with E5 compared to placebo receivers were also significantly more likely to experience resolution of organ failures. Significant reductions in morbidity and mortality associated with HA-1A's use were limited to patients with gram-negative bacteremia, and occurred even in patients with shock. Treatment with HA-1A also had a significant positive effect on resolution of the major complications of sepsis (shock, disseminated intravascular coagulation, acute renal failure, acute hepatic failure, or adult respiratory distress syndrome) in patients with documented gram-negative bacteremia. Both products appear to be safe, with generally mild, transient, and clinically insignificant adverse effects reported. |
| | |
Authors:
|
R Quintiliani; B Cooper; E Maderazo; C Nightingale |
Related Documents
:
|
3501966 - Hemoperfusion and immunocorrection in acute stage of severely burned patients. 3916776 - Pulmonary injury in burned patients. 10431986 - Electric burns: high- and low-tension injuries. 10206016 - The natural history of the systemic inflammatory response syndrome and the evaluation o... 15940556 - Relationship between clinically detected joint swelling and effusion diagnosed by ultra... 1238236 - Treadmill arrhythmias in patients with idiopathic hypertrophic subaortic stenosis. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Hospital formulary Volume: 27 ISSN: 0098-6909 ISO Abbreviation: Hosp Formul Publication Date: 1992 Jan |
Date Detail:
|
Created Date: 1992-03-13 Completed Date: 1992-03-13 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7508609 Medline TA: Hosp Formul Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 49-52, 54, 57-60 Citation Subset: H |
Affiliation:
|
Hartford Hospital, CT 06115. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
administration & dosage,
adverse effects,
therapeutic use* Clinical Trials as Topic Gram-Negative Bacterial Infections / complications, drug therapy* Humans Safety Survival Rate Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Taxation of nonprofit hospitals: a cost impact model.
Next Document: Pediatric emergency information sheet using a microcomputer.